Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
Early P 1 (1)
P 1 (1)

Trial Status

Recruiting2
Unknown1
Not Yet Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT07567196Recruiting

PET-Guided Resection in High-Grade Gliomas

NCT05989997Phase 1Completed

Phase I Clinical Trial of 68Ga-NOTA-SNA002

NCT06973798Not ApplicableNot Yet Recruiting

The Study on the Effectiveness of [68Ga]Ga-HBED-CC-DiAsp PET/CT in Calculating GFR and Predicting Residual Renal Function After Partial Nephrectomy

NCT06696326Not ApplicableRecruitingPrimary

A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer

NCT05490264Early Phase 1Unknown

[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors

Showing all 5 trials

Research Network

Activity Timeline